Introduction 49
Bladder cancer is the ninth most common cancer worldwide. 1 The majority of bladder 50 cancers are transitional cell carcinomas (TCC), of which 70-80% are non-muscle invasive 51 (NMIBC) at presentation.
2 Poorly differentiated 'high-grade' (HG)-NMIBC is a clinically 52 important sub-type, accounting for approximately 10-15% of all NMIBCs at presentation. 3, 4 , 53
These high-grade tumours are typically more aggressive than their low-and intermediate-54
grade counterparts, manifest by higher rates of recurrence and progression to invasive and 55 metastatic disease despite intensive and prolonged intravesical treatment. 5, 6 56 57
The majority of NMIBCs are thought to be consequent to, and represent initiation and 58 progression from, a complex interplay between sporadic, environmental, and heritable risk 59 factors, including those that impact upon genetic and epigenetic pathways. NMIBCs and 60 muscle invasive bladder cancers (MIBCs) have been shown to develop independently ('the 61 two pathway model') on the basis of gain of function fibroblast growth factor receptor 3 62 (FGFR3) mutations in NMIBC, and loss of function mutations in retinoblastoma 1 (RB1) and 63 tumour protein 53 (p53) in MIBC, [7] [8] [9] [10] and have been shown to evolve from different cell 64 types. 11, 12 However, the molecular pathways responsible for the evolution, outgrowth and 65 progression of HG-NMIBC have not been subject to comprehensive study or investigation; 66 indeed, it is currently unclear whether HG-NMIBCs arise as a discrete disease entity, 67 whether they represent step-wise progression from low-intermediate-grade NMIBC tumours, 68 or whether they sit at a molecular crossroads between NMIBC and MIBC. 7, 13 11 This 69 uncertainty is illustrated by the findings that high-grade tumours harbour abnormalities in 70 common with low-intermediate-grade NMIBC, such as mutations of FGFR3 and/or rat 71 sarcoma viral oncogene homolog (RAS) pathway genes 14, 15 , but also display extensive 72 genetic instability and compromised regulation of vital cellular processes more in keeping 73 with MIBC. 14, 16 74 Epigenetic modifications are frequently implicated in the development of human 75 malignancies, and in these cases, are typically apparent as inappropriate gene promoter 76
CpG island DNA methylation, histone tail modification(s), aberrant expression of micro-and 77 long non-coding-RNAs, and less frequently, loss of gene body/intergenic methylation. 17, 18 78 These heritable modifications, or epimutations, impact upon gene expression either alone or 79 in combination, and promote tumour evolution and/or progression by suppressing the 80 expression of growth inhibiting and/or apoptosis promoting genes, and less frequently by 81 leading to relaxed control of expression of growth promoting genes. 17, 19, 20 Figure S1 ). 106 107
In-house filtering criteria: 108
CpGs showing differential methylation in HG-NMIBC relative to normal bladder controls were 109 identified following a series of stringent filtering criteria, as described previously and shown 110
in Figure 1 . 25, 26 On the basis of these criteria, a total of 1,057 CpGs, representing 256 111 genes, were identified as hypermethylated (≥0.4 β-value increase) in 15 or more of the 21 112 high-grade tumours, relative to their mean values in the normal bladder controls. 113
114

Hierarchical clustering analyses: 115
The filtered dataset was next subject to unsupervised hierarchical cluster analysis ( Figure  116 2): the high-grade tumours cluster independently from the normal bladder control samples. 117
In these cases, methylation is barely detectable within the normal bladder samples, whereas 118 15 or more of the high-grade tumours show inappropriate methylation across all 1,057 CpG 119 dinucleotides, spanning 256 gene-promoter-associated CpG islands (Supplemental Table  120 S2). 121
122
Independent validation by Pyrosequencing: 123
We next selected 25 genes for independent validation by Pyrosequencing on the basis of 124 their frequent methylation in the discovery cohort that comprised 21 high-grade tumours. 125
These analyses revealed similar frequencies and mean levels of methylation as those 126 apparent from the BeadChip array for 24 of the 25 genes. As further confirmation, we 127 extended the Pyrosequence analyses to an independent investigation cohort of 30 HG-128 NMIBC tumours. Similar frequencies and mean levels of methylation between the discovery 129 and investigation cohorts reinforced our confidence in the array-derived data (Supplemental 130 Table S4 ). Similar to other groups 27 28 , we displayed these 140 methylation data, across the high-grade and low-intermediate-grade tumours and normal 141 controls, by heatmap (Figure 3) . This demonstrated heterogeneous patterns of methylation 142 across the 51 high-and 18 low-intermediate-grade tumours relative to the normal bladder 143 controls. Gene-specific differences in methylation were apparent between the high-grade 144 tumours and their low-intermediate-grade counterparts on visual inspection. Closer 145 examination of these data showed that the differences appeared to impact on either the 146 relative frequency and/or the mean levels of methylation between these tumour subtypes. As 147 examples of these differences, the ten most differentially methylated genes are shown in 148 
Mean levels of methylation in high-and low-intermediate-grade tumours: 158
The mean levels of methylation in the high-grade tumours were next assessed by 159
Pyrosequencing (right-sided panel of Table 1 
Gene Ontology analysis of inappropriately methylated genes: 182
Gene Ontology analyses of the 256 differentially methylated genes identified 'over-183 representation' of multiple categories of biological processes, molecular functions and 184 pathways. In particular, highly significant over-representation was identified for specific 185 biological processes, including regulation of RNA polymerase II activity and DNA 186 transcription, and for pathways involving cell adhesion and PI3K-Akt signalling 187 (Supplemental Table S5 genes, these analyses confirmed and reinforced the array-derived data.
34 35 36 These 211 analyses also showed that for the majority of regions investigated, methylation extended to 212 include contiguous promoter-associated CpG sites. On the basis of previous reports from 213 our own and other groups, 37 38 we employed stringent criteria (β-value differences ≥0.4) to 214 identify differentially methylated genes across multiple CpG sites; such criteria are more 215 consistently associated with bona fide changes in methylation, and are more likely to show 216 associations with gene expression. 37, 39 40, 41 
217
The analysis of the discovery cohort of high-grade NMIBC identified 1,057 CpGs, across 256 218 gene-promoter-associated CpG islands. Cluster analysis and heat map display of these 219 regions revealed extensive and frequent differential methylation in the tumours relative to 220 normal bladder controls. As our study represents the first 450K analysis of high-grade 221 bladder cancer a direct 'like-for-like' comparisons of our findings with those of other groups 222 was not possible; however, the number of differentially methylated sites we identified 223 appeared to be lower than those previously reported in other tumour types. outcome, similar to that described in colorectal, breast and lung cancers.
52-54
256
Although many of the novel genes we identified have not been previously reported in 257 bladder cancer, their inappropriate methylation, accompanied with gene-silencing, has been 258 reported in the context of other tumour types and suggests potential roles as tumour 259 suppressor genes. 55, 56 57 To determine associations between methylation and gene 260 expression, we confined our studies to genes showing frequent and/or high mean levels of 261 methylation. For the majority of gene-transcripts we investigated, promoter methylation was 262 negatively correlated with reduced transcript expression, although not significantly so (data 263 not shown). However, as described by our own and other groups, this may reflect a 264 passenger-driver phenomenon where, in the 'passenger' context, gene expression is not 265 directly influenced by the observed epigenetic modification(s).
58 59 However, for four of 266 seventeen transcripts we examined, significant correlations between methylation and 267 transcript expression were apparent. In these cases, and for the PON3, STAT5a and VAX2 268 genes, promoter methylation was significantly associated with reduced gene expression, 269 whilst the converse was true for the ARHGEF4 gene. Such associations are similar to those 270 described previously in multiple other cancers and in NMIBC. 20, 21 43 Indeed, for two of these 271 genes, PON3 and STAT5a, previous studies in mice and cell-line models have described 272 potential tumour suppressor roles. 
DNA extraction and bisulphite modification 306
Genomic DNA was extracted from tumour and control tissues using a standard phenol-307 chloroform procedure 64 , then bisulphite-converted using the EZ DNA Methylation Gold kit 308 (Zymo Research) as we have previously described.
37 Bisulphite-conversion of DNA was 309 confirmed in all cases by successful PCR using primers specific to bisulphite-converted DNA 310 (primer sequences in Supplemental Table S6 ). To increase the relative amount and stability 311 of bisulphite-converted DNA, whole-genome amplification (WGA) was performed as 312 previously described. 
Illumina 450K Methylation Bead-Array Analyses 316
Bisulphite-converted DNA from 21 bladder tumours and three normal controls was 317 hybridised to Infinium-based HumanMethylation450 BeadChip arrays (Illumina, San Diego, 318 CA, USA) to quantify DNA methylation at approximately 480,000 CpG positions across the 319 genome, representing more than 21,000 RefSeq genes. In this case, normal bladder was 320 used as control for consistency with previous array analyses 35, 47, 65 , and also to permit 321 comparisons with earlier reports of non-muscle invasive bladder cancer. Arrays were 322 processed according to the manufacturer's instructions (performed by Barts and the London 323
Genome Centre, UK), as described by us previously.
66
324
Raw array data were processed using GenomeStudio software and the bioinformatical 325 platform 'NIMBL', as we 67, 68 and others 69 have described. For each probe, the methylation 326 status was reported as a methylation 'β-value', where 'β' is defined as the ratio of the 327 methylated signal intensity over the summed intensity of the methylated and unmethylated 328 signals + 100. 40 β-values range from 0 (unmethylated) to 1 (fully methylated). NIMBL was 329 used to perform 'peak-based' correction, to adjust for potential differences in array probe-330 type sensitivity previously reported 33 ; all comparative analyses of high-grade tumours to 331 normal bladder controls, were performed on peak-based corrected β-values, as described by 332 us previously. 68 
333
Each array passed quality control assessment based upon the performance of internal 334 controls and the distribution of β-values across all array CpGs. As previously described β-values (preventing analyses of all samples). We also excluded all CpG loci on allosomes 338 (reducing confounding gender-based methylation differences). We used a series of stringent 339 filtering criteria, shown in Figure 1 and described in the Results section, to identify 340 inappropriate methylation, defined as a β-value difference ≥0.4, in tumour samples relative 341 to the mean of the normal bladder controls. 342
343
Unsupervised hierarchical clustering using average linkage criteria was performed using 344
Genesis software (v1.7.6).
70 Gene Ontology (GO) analyses were performed using 345 http://geneontology.org/ and http://gather.genome.duke.edu/, and Kyoto Encyclopaedia of 346
Genes and Genomes (KEGG) analyses with http://www.genome.jp/kegg/ online platforms, 347 respectively. Bonferroni correction 71 was employed in all GO and KEGG pathway analyses. 348 349
Technical validation of Methylation Bead-Chip Array Data 350
Five CpG loci encompassing a broad range of β-values derived from 450k array analyses, 351
were assessed by Pyrosequencing (described below), using identical samples, to 352 independently validate the array data (β-values vs. methylation %). Correlation between the 353 methods was assessed across a total of 120 CpGs using Spearman's rank correlation, as 354 shown in Supplemental Figure S1 . Primer sequences are provided in Supplemental Table  355 
S6. 356 357
Pyrosequencing™ of sodium bisulphite-converted DNA 358
Validation of array data (discovery cohort) and further quantitative assessment of 359 methylation in the independent (investigation) tumour cohort were performed by 360
Pyrosequencing of sodium bisulfite-converted DNA, as previously described by us 66 , using a 361 PyroMark Q24 Pyrosequencer, PyroMark Q24 Software 2.0 and PyroMark Gold Q24 362
Reagents. Dependent on the specific gene, and the density of CpGs within their promoter-363 associated CpG island, between five and nine consecutive CpG sites were assessed. 364
Promoter methylation was defined in tumours if the mean level of methylation across the 365 assessed CpG island was greater either than four standard deviations (4SD), or 20% above, 366 the mean of the normal controls. 37 The number of tumours methylated for any given gene 367 describes the frequency of methylation, whereas the mean percentage methylation per se of 368 all of the CpGs surveyed within a gene describes the mean level of methylation. 369
370
Quantitative RT-PCR 371
Total RNA was extracted from control and tumour samples using a standard guanidinium 372 thiocyanate-phenol-chloroform protocol 72 . Complementary DNA (cDNA) was synthesised as 373 described previously 73 . Thermal cycling using SYBR Green was as previously described 74 , 374
with target genes normalised to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as 375 the endogenous control gene (Supplemental Table S6 ). Relative quantification of transcript 376 expression was performed using the 2 -∆∆ cycle threshold (CT) method
75
, and as previously 377 
